HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Casal, A. J Articles by Ferrari, P. Search for Related Content PubMed PubMed Citation Articles by Casal, A. J Articles by Ferrari, P.

Division of Endocrinology, Diabetology & Nutrition, University Hospital, Geneva 1211, Switzerland
¹ Division of Nephrology, Inselspital, Berne 3010, Switzerland
² Department of Nephrology, Fremantle Hospital, University of Western Australia, Perth 6160, Australia

(Requests for offprints should be addressed to P Ferrari; Email: paolo.ferrari{at}health.wa.gov.au)

We have identified a novel cytosine/thymidine polymorphism of the human steroidogenic acute regulatory (StAR) gene promoter located 3 bp downstream of the steroidogenic factor-1 (SF-1)-binding site and 9 bp upstream of the TATA box (ATTTAAG). Carriers of this mutation have a high prevalence of primary aldosteronism. In transfection experiments, basal StAR promoter activity was unaltered by the mutation in murine Y-1 cells and human H295R cells. In Y-1 cells, forskolin (25 µM, 6 h) significantly increased wild-type promoter activity to 230±33% (P<0.05, n=4). In contrast, forskolin increased mutated promoter activity only to 150±27%, with a significant 35% reduction compared to wild type (P<0.05, n=3). In H295R cells, angiotensin II (AngII; 10 nM) increased wild-type StAR promoter activity to 265±22% (P<0.01, n=3), while mutated StAR promoter activity in response to AngII only reached 180±29% of controls (P<0.01, n=3). Gel mobility shift assays show the formation of two additional complexes with the mutated promoter: one with the transcription repressor DAX-1 and another with a yet unidentified factor, which strongly binds the SF-1 response element. Thus, this novel mutation in the human StAR promoter is critically involved in the regulation of StAR gene expression and is associated with reduced promoter activity, a finding relevant for adrenal steroid response to physiological stimulators.

This article has been cited by other articles:

				H. A. LaVoie and S. R. King Transcriptional Regulation of Steroidogenic Genes: STARD1, CYP11A1 and HSD3B Exp Biol Med, August 1, 2009; 234(8): 880 - 907. [Abstract] [Full Text] [PDF]